Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Reference Ranges and Association of Age and Lifestyle Characteristics with Testosterone, Sex Hormone Binding Globulin, and Luteinizing Hormone among 1166 Western Chinese Men

Reference Ranges and Association of Age and Lifestyle Characteristics with Testosterone, Sex Hormone Binding Globulin, and Luteinizing Hormone among 1166 Western Chinese Men

  • Xubo Shen, 
  • Ruifeng Wang, 
  • Na Yu, 
  • Yongjun Shi, 
  • Honggang Li, 
  • Chengliang Xiong, 
  • Yan Li, 
  • Ellen M. Wells, 
  • Yuanzhong Zhou


22 Dec 2016: Shen X, Wang R, Yu N, Shi Y, Li H, et al. (2016) Correction: Reference Ranges and Association of Age and Lifestyle Characteristics with Testosterone, Sex Hormone Binding Globulin, and Luteinizing Hormone among 1166 Western Chinese Men. PLOS ONE 11(12): e0168029. View correction


Decreased total testosterone (TT) is the recommended metric to identify age-related hypogonadism. However, average TT and the extent to which it varies by age, can vary substantially among different populations. Population-specific reference ranges are needed to understand normal versus abnormal TT levels. Therefore, the goal for this study was to describe androgen concentrations and their correlates among Western Chinese men. We completed a population-based, cross-sectional study including 227 young adults (YA) (20–39 years) and 939 older adults (OA) (40–89 years). We measured TT, sex-hormone binding globulin (SHBG), luteinizing hormone (LH), testosterone secreting index (TSI), and calculated free testosterone (cFT). Reference ranges for this population were determined using average YA concentrations. Multivariable regression models were used to predict hormone concentrations adjusting for age, waist-to-height ratio (WHR), marital status, education, occupation, smoking, alcohol, blood glucose, and blood pressure. Among OA, 3.8% had low TT, 15.2% had low cFT, 26.3% had low TSI, 21.6% had high SHBG, and 6.1% had high LH. Average cFT was significantly lower in OA (0.30 nmol/L; standard deviation (SD): 0.09) versus YA (0.37; SD: 0.11) but TT was not different in OA (16.82 nmol/L; SD: 4.80) versus YA (16.88; SD: 5.29). In adjusted models increasing age was significantly associated with increased SHBG or LH, and decreased cFT or TSI; however, TT was not significantly associated with age (β = 0.02 nmol/L; 95% confidence interval (CI): -0.01, 0.04). Higher WHR was associated with significantly decreased TT, SHBG, TSI, and LH. The only variable significantly related to cFT was age (β = -0.0033; 95% CI:-0.0037, -0.0028); suggesting that cFT measurements would not be confounded by other lifestyle factors. In conclusion, cFT, but not TT, varies with age in this population, suggesting cFT may be a better potential marker for age-related androgen deficiency than TT among Western Chinese men.


Late onset hypogonadism (LOH) [1] is a clinical and biochemical syndrome associated with advancing age and is characterized by sexual, psychological, and physical symptoms as well as serum testosterone concentrations below the reference range defined by typical values among young, healthy adult males [24]. LOH may significantly reduce quality of life and adversely affects the function of multiple organ systems [3, 5]; severe LOH is even associated with substantially higher risk of all-cause and cardiovascular mortality [6].

Descriptive epidemiology studies suggest this affects a substantial number of older men. Buvat et al. estimated androgen deficiency prevalence among aging men to be between 7% and 49% [7]. Incidence of total testosterone (TT) <325 ng/dL in United States males was ~20% among 60–69 year old men, ~30% among 70–79 year old men, and ~50% among men ≥ 80 years old [8]. Notably, greater incidence was found with reduced free testosterone index instead of TT [8]. Reported rates are lower when using a combination of androgen concentrations and reported symptoms, but are still of concern. A report from the Massachusetts Male Aging Study used a combination of multiple symptoms, TT, and free testosterone (FT) as diagnostic criteria reported prevalence of androgen deficiency at 5.9% among 40–49 year olds, 11.2% among 50–59 year olds, and 23.3% among 60–69 year olds [9]. Lower prevalence was reported from the European Male Aging Study: 2.1% among men between 40 and 79 years old using both androgen and symptom criteria [10].

As seen from the statistics above, age is strongly associated with androgen deficiency or LOH. In addition, lifestyle factors including obesity and smoking may also influence serum androgen concentrations [1115]. Several studies have observed that obese men tend to have lower TT and sex hormone binding globulin (SHBG), but not FT [1115]; tobacco consumption was positively associated with serum levels of TT and FT [11, 15].

A variety of criteria have been used in the literature to define androgen deficiency or LOH; this reflects the challenge within this field to develop detailed unified criteria. Guidelines from several professional societies (International Society of Andrology, International Society for the Study of the Aging Male, European Association of Urology, European Academy of Andrology, and American Society of Andrology) recommend decreased total testosterone as the primary marker of LOH [16, 17]. However, it is still challenging to implement this recommendation on a local level because average TT varies substantially in different populations; thus a specific concentration that might qualify as a decreased concentration within one population may not represent a decrease in another [8, 11, 14, 15, 1822]. Additionally, several researchers have noted that free testosterone may also be of value in identifying androgen deficiency of LOH because age-related decline in free testosterone is more consistently observed and of a greater magnitude than an age-related decline in total testosterone [15, 19, 21, 22].

Although reference ranges for androgen hormones have been described for the United States [5, 23, 24], Europe [2528], and some parts of Asia [4, 29], this information has rarely been described and still remains unclear for Chinese men [14, 30]. This information is important to help local clinicians accurately identify men who may be affected by LOH. Therefore, the goal of this research was to conduct a population-based study of Western Chinese men in order to establish average androgen concentrations as well as their correlation with age and lifestyle characteristics. This may suggest which hormones may be of most relevance for describing LOH within this population.


We conducted a population-based, cross-sectional study among adult males from Zunyi, Guizhou Province, China in 2013. Participants completed a questionnaire and brief clinical exam; hormone concentrations were determined using a fasting blood sample. This study was approved by the Ethical Committee Review Board of Tongji Medical College in the Huazhong University of Science and Technology. All subjects provided written informed consent prior to participating in the study.

Study Setting and Subjects

Zunyi has a population of 1.2 million people living in 80 communities located <50 kilometers from the city center. A stratified cluster design was used to select communities sampled for this study. Communities were stratified by urban, suburban, and rural status. About 10% of communities within the three strata were selected for inclusion in this study: 2 urban communities (Jiaotong, Yanhong), 2 suburban communities (Heping, Jianguo), and 3 rural communities (Gema, Tiangou, Wuxing). Physicians in each of these communities contacted adult males to inform them about the study and invite them to participate. All data for this study was collected between August 20 and September 20, 2013.

A total of 1213 Chinese adult men were identified as potential study participants. Study exclusion criteria were based on reports from previous studies [16]. Additionally, criteria for this study are identical to other, ongoing studies in China [31]; this intentional design will improve our ability to compare results across the entire country in the future. Inclusion criteria were male sex, age between 20–89 years, and residence in one of the communities selected for inclusion in this study. Men were excluded for the following reasons: diagnosed cardiac, kidney, or liver disease (n = 11), pituitary-testicular disease (n = 1), drug abuse (n = 4). Additional exclusion criteria include incomplete or illogical questionnaire responses (n = 29) and insufficient or non-fasting blood sample (n = 2). After exclusions, 1166 subjects (1166/1213, 96.12%) participated in this study.

Questionnaire and Physical Examination

All questionnaire, physical exam, and blood sample data were anonymized using a participant identification code to help protect the confidentiality of study participants.

Participants completed a questionnaire designed to collect information on demographics and socioeconomic status. We assessed age, medical history, smoking, alcohol use, and obesity as previous studies have identified these as potentially significant factors in hormone concentrations [11, 13, 26, 32]. Occupation, marital status, and years of education were additional variables used in this study to classify socioeconomic characteristics. Variables were categorized using standard clinical classifications or sociodemographic attributes. A male physician was present to assist with the questionnaire completion upon participant request; no other individuals were present for questionnaire completion.

A physical examination was conducted by trained study staff to measure height, weight, waist circumference, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Body mass index (BMI) (a measure of general obesity) and waist-to-height ratio (WHR) (a measure of central obesity) were calculated as: BMI = weight (kg) / (height (m))2 and WHR = waist circumference (cm) / height (cm). A cutoff value of 0.5 (≤ 0.5 = normal weight; >0.5 = overweight or obese) was used for WHR, as recommended previously [33].

Trained nurses collected blood samples from 7:00 to 11:00 AM following an overnight fast. Although testosterone concentrations do vary diurnally, this time period represents peak or near-peak concentrations [34], and this time period is therefore recommended by the International Society of Andrology, the International Society for the Study of the Aging Male, the European Association of Urology, European Association of Andrology, and the American Society of Andrology [16] to collect blood for testosterone evaluation. Venous blood was centrifuged for 15 min at 4°C to obtain serum within 1 hour, and serum was stored at -80°C until analysis. Whole blood was used to assess blood glucose using standard clinical methods.

Serum Hormone Assessments

TT, SHBG and luteinizing hormone (LH) were measured by chemiluminescent immunoassays on a Beckman Access Immunoassay system (Beckman Coulter, Inc., Brea, CA, USA). It is difficult and expensive to directly measure FT; however, calculated free testosterone (cFT) is highly correlated with FT and has been used in previous research studies [35, 36]. cFT was quantified using Vermeulen’s formula [35]. Testosterone secreting index (TSI) was defined as TT (nmol/L) / LH (IU/L).

Statistical Analyses

Questionnaire and hormone data were proofread and entered in EPIdata version 3.02 (Odense, Denmark), analyses were performed with SPSS version 18.0 (Armonk, NY, USA), and graphics were produced using Stata 13.0 (College Station, TX, USA). A p-value <0.05 was considered statistically significant.

Methods to determine average reference hormone concentrations were based on published examples or recommendations from the Japanese Urological Association [37]. Participants were classified as younger adults (YA) (20–39 years) or older adults (OA) (40–89 years). The group of YA was used to estimate reference concentrations for hormones within this population. The reference range was calculated using a nonparametric method: abnormal hormone concentrations were defined as values below the 5th percentile for TT, cFT and TSI [16] and concentrations higher than the 95th percentile for SHBG [13] and LH [38]. Reference concentrations, abnormal cutoffs, and the percentage of OA considered to be abnormal are presented.

The influence of age and other sociodemographic variables on hormone concentrations was assessed using linear regression models. Bivariate associations between hormone concentrations and demographic or lifestyle characteristics were assessed using unadjusted linear regression models and Spearman correlation coefficients. We created nonparametric lowess smoothing curves of each hormone versus age and stratified by high/low WHR. Stratification by weight was conducted because weight has been previously identified as an important variable influencing age-related hormone change [11]. We used Spearman correlation coefficients to assess the potential for multicollinearity between age and lifestyle variables. A high correlation (Spearman’s ρ>0.7, p<0.01) was found for BMI with WHR and SBP with DBP; therefore, we excluded BMI and DBP from multivariable analysis as WHR and SBP are thought to be better predictors of future health status [39, 40].

Multivariable linear models were created for each hormone as a dependent variable, and our a priori list of demographic and lifestyle characteristics as independent variables. Independent variables for each model included age (continuous), WHR (≤0.5 vs. >0.5), blood glucose (continuous), systolic blood pressure (SBP) (continuous), occupation (farmer vs. not), education level (≤5 vs. >5 years), marital status (married vs. not), smoking status (current vs. never or former), alcohol use (current vs. never or former), and history of vasectomy (yes vs. no).


Demographic and Lifestyle Characteristics

This study included 227 YA and 939 OA (Table 1). Overall, participants’ average age was 51.6 years, 82.0% were farmers, 93.5% were married, 78.8% were current smokers, and 57.3% currently drink alcohol. OA had significantly higher average WHR (0.51; standard deviation (SD) = 0.08), SBP (130.64 mmHg, SD = 19.54), and DBP (84.43 mmHg, SD = 12.28) compared to YA, where average WHR = 0.50 (SD = 0.06), SBP = 121.27 mmHg (SD = 14.58), and DBP = 81.16 mmHg (SD = 10.56); p<0.05 for all comparisons. The proportion of men who were farmers, had less education, current smokers, had a vasectomy, or never/former drinkers was significantly higher among OA compared to YA; p<0.05 for all comparisons. There was no statistically significant difference for the remaining characteristics between OA and YA.

Table 1. Selected characteristics among young adults (n = 227), older adults (n = 939) and the total study population (n = 1166).

Hormone Concentrations and Reference Values

Reference concentrations for hormones, based on YA averages, are presented in Table 2. Among YA, average hormone concentrations were TT: 16.9 nmol/L (SD: 5.3); SHBG: 31.7 (SD: 14.6); cFT: 0.4 nmol/L (SD: 0.11); TSI: 4.8 (SD: 2.4) and LH: 4.2 IU/L (SD: 2.3). The lower cutoff values for TT, cFT and TSI were 9.16 nmol/L, 0.22 nmol/L and 1.89nmol/L, respectively; whereas the higher cutoff values for SHBG and LH were 58.26 nmol/L and 15.35 IU/L, respectively.

Table 2. Mean, median and interquartile range of hormone concentrations among young adults (n = 227) and calculated cutoff values.

Average hormone concentrations for the entire study population are presented in Table 3. Average serum TT concentration were 16.83 nmol/L (SD = 4.90) overall; 16.88 nmol/L (SD = 5.29) among YA; and 16.82 nmol/L (SD = 4.80) among OA. There was no difference in TT among YA versus OA. Meanwhile, cFT was significantly lower among OA versus YA: this was 0.37 nmol/L (SD = 0.11) among YA and 0.30 nmol/L (SD = 0.09) among OA. TSI were also significantly lower among OA versus YA whereas LH and SHBG were significantly increased among OA versus YA.

Table 3. Mean (SD) hormone concentrations, stratified by selected characteristics, n = 1166.

The percent of older adults below the reference range for TT, cFT and TSI was 3.8% (95% CI: 3.2%, 4.4%), 15.2% (95% CI: 14.1%, 16.3%), and 26.3% (95% CI: 24.9%, 27.8%), respectively. The percent of older adults higher than the reference range for SHBG and LH was 21.6% (95% CI: 20.2%, 23.0%) and 6.1% (95% CI: 5.3%, 6.9%) respectively. Graphs of the percent abnormal concentrations by age are shown in Fig 1. The percent of abnormal concentrations for TT does not change with age (p = 0.632, likelihood ratio test); however the percentage of abnormal SHBG (p<0.001), cFT (p<0.001), TSI (p<0.001), and LH (p<0.001) increase significantly with increasing age.

Fig 1. Percent abnormal hormone concentrations by age among older men.

Mean (diamond) and 95% confidence interval (line) of the percent abnormal hormone concentrations among men, by decade of age, based on cutoff values shown in Table 2.

Unadjusted Associations of Hormones with Lifestyle/Demographics

We compared hormone concentrations across categories of demographic and lifestyle variables (Table 3). TT was significantly associated with WHR, BG, SBP, farming, and marital status; notably, TT was not significantly associated with age. SHBG was significantly associated with age, WHR, farming, education, smoking, and alcohol use. cFT was associated with age, BG, SBP, farming and education. TSI was significantly associated with age, WHR, BG, SBP, farming, and education. There was a statistically significant association of LH with age, WHR, SBP, farming, education, marital status, and alcohol use.

Trends in hormone concentrations by age shown in Fig 2; these are stratified by WHR (≤0.5 versus >0.5). There is a statistically significant decrease in TT (p≤0.0001) and SHBG (p≤0.001) among men with a higher WHR; differences for other hormones may vary depending on age.

Fig 2. Change in hormone concentration with age, stratified by waist-to-height ratio.

These are smoothed lowess curves where the solid line is WHR ≤ 0.5 and the dashed line is WHR > 0.5. Individual observations are represented with circle (WHR ≤ 0.5) and plus (WHR >0.5) markers. The reference line indicates the reference hormone concentration (the mean hormone concentration among 20–39 year olds). TT = total testosterone (reference = 16.88 nmol/L); SBGH = sex binding globulin hormone (reference = 31.67 nmol/L); cFT = calculated free testosterone (reference = 0.37 nmol/L); TSI = testosterone secreting index (reference = 4.76); LH = luteinizing hormone (reference = 4.20 IU/L).

Adjusted Associations of Hormones with Lifestyle/Demographics

Results from models predicting hormone concentrations by age, are presented in Table 4; these are adjusted for WHR category, blood glucose, SBP, farming vs. not, education level, marital status, smoking status, alcohol use, and history of vasectomy. In the adjusted model, there was a statistically significant decrease in TT related to higher WHR (adjusted β (βadj) = -2.87; 95% confidence interval (95% CI): -3.41, -2.32), BG (βadj = -0.37; 95% CI: -0.54, -0.20), and SBP (βadj = -0.02; 95% CI: -0.04, -0.01); however, there was no association with age. SHBG increased with aging (βadj = 0.76; 95% CI: 0.68, 0.85), but was reduced with increasing WHR (βadj = -11.59; 95% CI: -13.59, -9.61), BG (βadj = -0.98; 95% CI: -1.61, -0.35), SBP (βadj = -0.14; 95% CI: -0.19,-0.09), and among famers (βadj = -2.66; 95% CI: -5.23, -0.09). For cFT, the only variable which had a statistically significant association was age (βadj = -0.0033; 95% CI: -0.0037, -0.0028). TSI decreased with increased age (βadj = -0.06; 95% CI: -0.07, -0.05) and higher WHR (βadj = -0.42; 95% CI: -0.64, -0.20). LH increased with aging (βadj = 0.17; 95% CI: 0.14, 0.19) and among men with less education (βadj = -1.34; 95% CI: -2.31, -0.38), but decreased among married men (βadj = 1.30; 95% CI: 0.21, 2.39), among men with higher WHR (βadj = -0.78; 95% CI: -1.33, -0.23).

Table 4. Multivariable linear regression coefficient (95% confidence interval) for hormone concentrations related to selected characteristics, n = 1166.


This study was designed to assess mean and reference concentrations of androgen hormones and determine the relationship of androgen hormone concentrations with age and other demographic and lifestyle characteristics among in adult Western Chinese males. A major strength of this work is that it is a large study, which increases its external validity and that we were able to control for numerous potential confounding variables. This is also the first study to be completed in Western Chinese men, and one of only a handful completed in China: as such, this study provides valuable information regarding geographic variability in age-related androgen concentrations.

There are a few limitations to this study. As a cross-sectional study, our results do not provide direct evidence for causal factors for testosterone concentrations. The original study design was a stratified, population-based sample of adult males from Zunyi; however, as key data regarding recruitment and enrollment were not recorded, we are unable to calculate a response rate or unequivocally verify that our study population accurately reflects all adult males from Zunyi. Nonetheless, we did succeed in enrolling large population of adult males from a representative sample of geographic across the Zunyi region; as many sociodemographic variables correlated with geographic region it is likely that we were still able to achieve a population sample that reflects the variation seen among males in Zunyi. Additionally, in contrast to several other well-regarded studies in this area [16], we did not exclude participants on the basis of prostate cancer or immune diseases. As such, our population likely represents a somewhat less healthy sample of adults, and our results should be interpreted accordingly.

Some additional limitations lie within assessment of testosterone and other hormones. Our results were based on a single testosterone measurement, which may not reflect a long-term average concentration. However, we would expect any variation to be randomly distributed in the population, and as we have a large sample size we would expect that our average estimates still provide a reliable representation of testosterone concentrations within this population. Additionally, as there was a four-hour period over which blood samples were collected, it is possible that diurnal variation may have affected our measured concentrations. More specifically, we may have included some values that were slightly less than the peak testosterone concentrations. Notably, the timing of blood collection was unrelated to the participant’s age. Thus, while we might expect mean hormone concentrations overall to be somewhat lower and their variance increased by the inclusion of measurements that are just outside of the peak daily values, we would expect this to be independent of age. It is also possible that the increased variance may have somewhat reduced our power to detect changes in hormone concentrations; however, given that we were successful in enrolling a large sample of men, and that our protocols are consistent with recommendations from several major professional societies [16], the likely influence of blood collection timing on our results is likely to be minimal.

Testosterone production is regulated by the hypothalamic-pituitary-testicular axis. The hypothalamus releases gonadotropin-releasing hormone, which in turn triggers the pituitary gland to produce LH and follicle stimulating hormone (FSH). LH travels to the testis, where it interacts with Leydig cells to produce testosterone [41]. High concentrations of free testosterone will inhibit LH production [42, 43], but in conditions with decreased free testosterone LH production would be increased. Some testosterone becomes tightly bound to SHBG whereas the remainder is considered to be free testosterone, and is either loosely bound to albumin or unbound to proteins [36]. Free testosterone can enter cells and interact directly which androgen receptors; thus it is considered the bioavailable fraction, or the fraction responsible for the biological activity of testosterone [44].

Our analysis identified a cutoff value for the lower limit of cFT as 0.22 nmol/L, and for TT as 9.16 nmol/L. These are both similar to previously reported cutoff estimates [10, 45].

Our results indicated increases in average serum level for both SHBG and LH, a decrease in average serum level for cFT, a measure of free testosterone, associated with increasing age. Additionally, we observed that with increasing age there was an increase in the proportion of adults with SHBG or LH concentrations higher than the reference range and cFT or TSI concentrations below the reference range. There was no change in either the average serum level or proportion of individuals under the reference range for TT with increasing age. The true mechanism for this is still unknown. One possible explanation is that LH production increased as a result of lower FT. However, it has been shown that with aging the number of LH receptors decreases: thus, increased LH may not have a substantial change on the amount of testosterone produced [38]. Meanwhile, the simultaneous increase in SHBG would result in much of the LH-triggered testosterone production to be bound rather than free testosterone. Thus, although increased testosterone production was signaled, the result may be to maintain total testosterone rather than free testosterone concentrations.

Our main finding that we did not observe a significant reduction in serum level and the proportion of men with low TT with aging is not consistent with several large population studies. The Massachusetts Male Aging Study, the Baltimore Longitudinal Study of Aging and an European Male Aging Study observed a decline of TT with aging [8, 11, 19]. Similar results were evident in an unadjusted baseline analysis of 3200 men from 8 different European countries within the European Male Aging Study; however, this association was no longer statistically significant after adjusting for confounders [46]. Our results are consistent with several cross-sectional studies completed among male Japanese office workers [22], healthy adult Chinese men [21], and most recently, among 1093 healthy men from Shanghai, China [14]. It is possible that geographic variability in genetics or environment may contribute to the differences in TT trends with age across these studies. Another observation from our work is the significant decline in serum level and an increase in the proportion of men with low cFT, an indicator of free testosterone, with increased age. This observation is consistent with the above-mentioned studies, regardless of their geographic location [19, 21, 22, 46]. Additionally, all of these studies consistently demonstrate that decreases in free testosterone are much greater in magnitude compared to decreases in total testosterone, regardless of whether a TT decrease was statistically significant.

It is possible that increased weight may also play a role in affecting hormone concentrations. Our adjusted regression models show a strong association between WHR with reduced TT and SHBG, but not with cFT. Prior cross-sectional studies have also identified significant inverse correlations of BMI, WHR, or both with TT [12, 14, 15, 21, 46] or SHBG [1315, 21, 46], although not all studies have found significant associations [22]. These results are also supported by results from longitudinal studies which found increased obesity was associated with decreased TT and SHBG while decreased obesity was associated with increased TT and SHBG [11, 47]. Several studies suggest a potential mechanism for these observations: obesity-induced increases in estrogen are thought to play a major role in determining negative feedback at the pituitary level, and insulin resistance may also contribute to the low testosterone levels seen in obese men [4850]. For example, increased free estradiol in older men has been associated with decreased SHBG and increased free testosterone, without a change in TT [51]. This may represent an alternative or additional mechanism to the increased LH production referenced above.

No association of obesity with free testosterone was found in Japanese and Chinese cohorts [12, 22], similar to our results; however, both Wu et al. and Svartberg et al. report inverse, cross-sectional associations of free testosterone with BMI [15, 46]. Interestingly, these initial observations suggest that there may also be an Asian/non-Asian difference in association of free testosterone with obesity, but, as relatively fewer studies have explored obesity and free testosterone as opposed to TT, this should be confirmed with additional studies.

The 2010 Endocrine Society guidelines recommend using both a measurement of low serum TT concentrations and the presence of symptoms or signs to diagnose Androgen Deficiency Syndromes in men [52]. Free or bioavailable testosterone assessment is only recommended among those whose total testosterone is borderline or when an abnormality in SHBG is suspected [52]. Although TT has been widely used as a diagnostic tool in many areas, particularly Western nations [3, 10, 48], there is still debate as to whether this is the best option [11, 13, 18, 19]. Free testosterone may also be a better predictor of clinical symptoms compared to TT: a recent study by Antonio et al. analyzed over 3000 community-dwelling men from the European Aging Male study and found that men with low free testosterone but normal TT experienced hypogonadal symptoms whereas men with normal free testosterone but low TT did not [28]. However, there is some conflicting evidence regarding the predictive ability of free testosterone. Ramasamy et al. performed a chart review of over 3000 men attending an outpatient men’s health clinic and did not find any association of hypogonadal symptoms with free testosterone among men with near-normal TT [53].

Despite the lack of a clear trend in the associations and predictive ability of total versus free testosterone, evidence from Asian populations does appear to be consistent in identifying that free testosterone, but not total testosterone, has a significant inverse association with age [4, 21, 22]; this is also consistent with the present study. For these reasons free testosterone, specifically cFT, has been recommended for use as a diagnostic tool in place of TT for Asian populations [4, 22]. In addition, our results indicate that the only covariate that was significantly associated with a decline in cFT was aging, suggesting cFT in our population is not influenced by demographic and lifestyle factors such as obesity, diabetes, smoke and alcohol use. This was not true for the other testosterone measures we evaluated, and is further evidence that cFT may be a better predictor of age-related androgen decline, as clinicians would not need to account for confounding from other demographic and lifestyle factors. Taken together, this evidence suggests cFT would be a better potential marker than TT for age-related testosterone decline among Western Chinese men.


In this population-based study of Western Chinese men, we found an independent association of reduced cFT concentrations with aging while serum TT concentrations did not change with age. Additionally, LH and SHBG concentrations significantly increased with age, while FTI and TSI concentrations significantly decreased with age. Central obesity was significantly and inversely correlated to serum TT and SHBG. Our data suggest cFT might be a good potential marker for age-related androgen deficiency in this population.

Supporting Information

S1 File. Questionnaire (Chinese/English).

The entire questionnaire used in this project, in Chinese; questions used in the present analysis are also translated into English.



The authors extend their thanks to the research team and the seven communities involved with this work for their support and cooperation.

Author Contributions

  1. Conceptualization: CX HL YZ.
  2. Data curation: XS RW NY YS YZ.
  3. Formal analysis: XS YZ.
  4. Funding acquisition: YZ CX HL.
  5. Investigation: XS RW NY YS YZ.
  6. Methodology: YZ CX HL YL.
  7. Project administration: YZ CX.
  8. Resources: XS RW NY YS YL YZ.
  9. Software: XS EMW YZ.
  10. Supervision: YL.
  11. Validation: EMW XS RW NY YS HL CX YL YZ.
  12. Visualization: XS EMW YZ.
  13. Writing – original draft: XS YZ.
  14. Writing – review & editing: EMW YZ.


  1. 1. Bassil N. Late-onset hypogonadism. Medical Clinics of North America. 2011;95(3):507–23. pmid:21549875
  2. 2. Jones TH. Late onset hypogonadism. British Medical Journal. 2009;338:b352. pmid:19218325
  3. 3. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. European Journal of Endocrinology. 2008;159(5):507–14. pmid:18955511
  4. 4. Iwamoto T, Yanase T, Horie H, Namiki M, Okuyama A. Late-onset hypogonadism (LOH) and androgens: validity of the measurement of free testosterone levels in the diagnostic criteria in Japan. International Journal of Urology. 2009;16(2):168–74. pmid:19054164
  5. 5. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). Journal of Clinical Endocrinology and Metabolism. 2012;97(5):1508–16. pmid:22419720
  6. 6. Pye SR, Huhtaniemi IT, Finn JD, Lee DM, O'Neill TW, Tajar A, et al. Late-onset hypogonadism and mortality in aging men. Journal of Clinical Endocrinology and Metabolism. 2014;99(4):1357–66. pmid:24423283
  7. 7. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. Journal of Sexual Medicine. 2013;10(1):245–84. pmid:22971200
  8. 8. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism. 2001;86(2):724–31. pmid:11158037
  9. 9. Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism. 2004;89(12):5920–6. pmid:15579737
  10. 10. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine. 2010;363(2):123–35. pmid:20554979
  11. 11. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. European Journal of Endocrinology. 2013;168(3):445–55. pmid:23425925
  12. 12. Cao J, Chen T-m, Hao W-j, Li J, Liu L, Zhu B-p, et al. Correlation between sex hormone levels and obesity in the elderly male. Aging Male. 2012;15(2):85–9. pmid:22452321
  13. 13. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM. The association of obesity with sex hormone-binding globulin is stronger than the association with ageing–implications for the interpretation of total testosterone measurements. Clinical Endocrinology. 2015;83(6):828–33. pmid:25777143
  14. 14. Liu Z, Liu J, Shi X, Wang L, Yang Y, Tao M. Dynamic alteration of serum testosterone with aging: a cross-sectional study from Shanghai, China. Reproductive Biology and Endocrinology. 2015;13:111. Epub 2015/10/01. pmid:26419465
  15. 15. Svartberg J, Midtby M, Bonaa KH, Sundsfjord J, Joakimsen RM, Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. European Journal of Endocrinology. 2003;149(2):145–52. pmid:12887292
  16. 16. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12(1):5–12. pmid:18763169
  17. 17. Lunenfeld B, Saad F, Hoesl C. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male. 2005;8(2):59–74. pmid:16096160
  18. 18. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. Journal of Clinical Endocrinology and Metabolism. 2007;92(9):3599–603. pmid:17595245
  19. 19. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. Journal of Clinical Endocrinology and Metabolism. 2002;87(2):589–98. pmid:11836290
  20. 20. Kelsey TW, Li LQ, Mitchell RT, Whelan A, Anderson RA, Wallace WHB. A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years. PLoS One. 2014;9(10):e109346. pmid:25295520
  21. 21. Li JY, Li XY, Li M, Zhang GK, Ma FL, Liu ZM, et al. Decline of serum levels of free testosterone in aging healthy Chinese men. Aging Male. 2005;8(3–4):203–6. pmid:16390747
  22. 22. Fukai S, Akishita M, Miyao M, Ishida K, Toba K, Ouchi Y. Age-related changes in plasma androgen levels and their association with cardiovascular risk factors in male Japanese office workers. Geriatrics and Gerontology International. 2010;10(1):32–9. pmid:20102380
  23. 23. Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. Journal of Clinical Endocrinology and Metabolism. 2007;92(11):4241–7. pmid:17698901
  24. 24. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. Journal of Clinical Endocrinology and Metabolism. 2011;96(8):2430–9. pmid:21697255
  25. 25. Nieschlag E, Swerdloff R, Behre H, Gooren L, Kaufman J, Legros J, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. European Urology. 2005;48(1):1–4. pmid:15951102
  26. 26. Deutschbein T, Mann K, Petersenn S. Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Influence of Age and Body Mass Index and Establishment of Sex-Specific Reference Ranges. Hormone and Metabolic Research. 2015;47(11):846–54. pmid:25565093
  27. 27. Friedrich N, Volzke H, Rosskopf D, Steveling A, Krebs A, Nauck M, et al. Reference ranges for serum dehydroepiandrosterone sulfate and testosterone in adult men. Journal of Andrology. 2008;29(6):610–7. pmid:18599883
  28. 28. Antonio L, Wu FC, O’Neill TW, Pye SR, Ahern TB, Laurent MR, et al. Low Free Testosterone is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. Journal of Clinical Endocrinology and Metabolism. 2016;101(7):2647–57. pmid:26909800
  29. 29. Moon DG, Kim JW, Kim JJ, Park KS, Park JK, Park NC, et al. Prevalence of symptoms and associated comorbidities of testosterone deficiency syndrome in the Korean general population. Journal of Sexual Medicine. 2014;11(2):583–94. pmid:24274237
  30. 30. Qin X, Lv H, Mo Z, Chen Z, Lin L, Peng T, et al. Reference intervals for serum sex hormones in Han Chinese adult men from the Fangchenggang Area Male Health and Examination Survey. Clinical Laboratory. 2012;58(3–4):281–90. pmid:22582502
  31. 31. Liu ZY, Zhou RY, Lu X, Zeng QS, Wang HQ, Li Z, et al. Identification of late-onset hypogonadism in middle-aged and elderly men from a community of China. Asian Journal of Andrology. 2016;18(5):747–53. pmid:26354142
  32. 32. Jensen TK, Swan S, Jorgensen N, Toppari J, Redmon B, Punab M, et al. Alcohol and male reproductive health: a cross-sectional study of 8344 healthy men from Europe and the USA. Human Reproduction. 2014;29(8):1801–9. pmid:24893607
  33. 33. Savva SC, Lamnisos D, Kafatos AG, Savva S, Lamnisos D, Kafatos A. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes, Metabolic Syndrome and Obesity. 2013;6:403–19. pmid:24179379
  34. 34. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clinical Endocrinology. 2003;58(6):710–7. pmid:12780747
  35. 35. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism. 1999;84(10):3666–72. pmid:10523012
  36. 36. Kacker R, Hornstein A, Morgentaler A. Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male. 2013;16(4):164–8. pmid:24090209
  37. 37. Namiki M, Akaza H, Shimazui T, Ito N, Iwamoto T, Baba K, et al. Clinical practice manual for late-onset hypogonadism syndrome. International Journal of Urology. 2008;15(5):377–88. pmid:18452452
  38. 38. Midzak AS, Chen H, Papadopoulos V, Zirkin BR. Leydig cell aging and the mechanisms of reduced testosterone synthesis. Molecular and Cellular Endocrinology. 2009;299(1):23–31. pmid:18761053
  39. 39. Ashwell M, Cole TJ, Dixon AK. Ratio of waist circumference to height is strong predictor of intra-abdominal fat. British Medical Journal. 1996;313(7056):559. pmid:8790002
  40. 40. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Annals of Internal Medicine. 2003;138(1):10–6. pmid:12513039
  41. 41. Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: possible Leydig cell desensitization to endogenous LH signaling—a clinical research center study. Journal of Clinical Endocrinology and Metabolism. 1995;80(10):3025–31. pmid:7559891
  42. 42. Baker H, Santen R, Burger H, De Kretser D, Hudson B, Pepperell R, et al. Rhythms in the secretion of gonadotropins and gonadal steroids. Journal of Steroid Biochemistry. 1975;6(5):793–801. pmid:1102804
  43. 43. Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Twenty-Four-Hour Rhythms in Plasma Concentrations of Adenohypophyseal Hormones Are Generated by Distinct Amplitude and/or Frequency Modulation of Underlying Pituitary Secretory Bursts. Journal of Clinical Endocrinology and Metabolism. 1990;71(6):1616–23. pmid:2172282
  44. 44. Hammond GL, Wu T-S, Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. Current Opinion in Endocrinology, Diabetes and Obesity. 2012;19(3):183–9. pmid:22531107
  45. 45. Anawalt BD, Hotaling JM, Walsh TJ, Matsumoto AM. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. Journal of Urology. 2012;187(4):1369–73. pmid:22341266
  46. 46. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. Journal of Clinical Endocrinology and Metabolism. 2008;93(7):2737–45. pmid:18270261
  47. 47. Shi Z, Araujo AB, Martin S, O'Loughlin P, Wittert GA. Longitudinal changes in testosterone over five years in community-dwelling men. Journal of Clinical Endocrinology and Metabolism. 2013;98(8):3289–97. pmid:23775354
  48. 48. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Practice and Research in Clinical Endocrinology and Metabolism. 2013;27(4):557–79. pmid:24054931
  49. 49. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. Journal of Endocrinological Investigation. 2011;34(7):557–67. pmid:21720206
  50. 50. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current Diabetes Reviews. 2012;8(2):131–43. pmid:22268394
  51. 51. Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, et al. Testosterone and estradiol among older men. Journal of Clinical Endocrinology and Metabolism. 2006;91(4):1336–44. pmid:16368750
  52. 52. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2010;95(6):2536–59. pmid:20525905
  53. 53. Ramasamy R, Golan R, Wilken N, Scovell JM, Lipshultz LI. Association of Free Testosterone With Hypogonadal Symptoms in Men With Near-normal Total Testosterone Levels. Urology. 2015;86(2):287–90. pmid:26199166